. 2015 Apr 14;21(14):4334–4344. doi: 10.3748/wjg.v21.i14.4334

Table 1.

Characteristics of 15 studies included in the meta-analysis

Ref.	Year	Country	Subject					MRI				Result
Ref.	Year	Country	Patients (n)	Age (yr)	Lesions (n)	Lesion type	Size (cm)	Type	Sequence	Contrast agent	Dose	Iso-/hypo	Hyper-
Harisinghani et al[12]	1997	United States	35	46	15	Hemangioma	NC	1.5T	T2WI	Code-7227	1.1 mg Fe/kg	13	2
					17	Metastases	NC					0	17
					6	HCC	NC					2	4
Imai et al[19]	2000	Japan	27	62	6	DN	1.6	1.5T	T2*WI	Ferumoxide	10 μmol/kg	6	0
					13	WD-HCC	1.6					11	2
					10	MD-HCC	1.6					0	10
					8	PD-HCC	1.6					0	8
Lim et al[15]	2001	South Korea	68	51	10	WD-HCC	2.1	1.5T	T2*WI	Ferumoxide	15 μmol/kg	6	4
					69	MDPD-HCC	5.3					0	69
					19	DN	0.8					19	0
Zheng et al[11]	2002	China	43	51	22	HCC	< 3	1.5T	T2WI	Feridex	0.05 mL/kg	0	22
					7	Other malignancy	< 3					0	7
					4	Cirrhotic nodules	< 3					4	0
					5	Hemangioma						0	5
					5	FNH						0	5
					4	Others						0	4
Zhang et al[20]	2003	China	30	50	30	HCCs	NC	0.5T	T2WI	Feridex	0.56 mL/kg	0	30
Zhang et al[20]	2003	China	30	50	6	Regenerative nodules						6	0
Suzuki et al[21]	2004	Japan	45	66	41	HCCs	2.26	1.5T	T2*WI	Ferumoxide	0.05 mL/kg	7	34
Suzuki et al[21]	2004	Japan	45	66	11	Benign						10	1
Kato et al[22]	2004	Japan	43	66	17	WD-HCC	3.00	1.5T	T2*WI	Ferumoxide	10 mmol/kg	4	13
					28	MD-HCC	3.00					1	27
					6	PD-HCC	3.20					0	6
Inoue et al[24]	2005	Japan	49	67	20	WD-HCC	2.70	1.5T	T2*WI	Ferumoxide	0.016 mL/kg	4	16
					20	MDPD-HCC						0	20
					9	DNs						8	1
Kobayashi et al[9]	2007	Japan	10	45	6	DNs	NC	1.5T	T2WI	Ferucarbotran	NC	6	0
Kobayashi et al[9]	2007	Japan	10	45	4	HCC						0	4
Park et al[18]	2009	South Korea	114	55	37	WD-HCC	2.38	3.0T	T2*WI	Ferucarbotran	8 mmol/kg	20	17
					156	MDPD-HCC	4.10					6	149
					23	DNs	1.28					22	1
Macarini et al[7]	2009	Italy	22	53	14	HCC	1.70	1.5T	T2*WI	Ferumoxide	NC	0	14
					3	WD-HCC
					11	MDPD-HCC
					4	DN with HCC	2.10					0	4
					39	DNs	0.80					39	0
					2	Cystadenoma	1.20					2	0
Yoon et al[16]	2009	South Korea	28	51	33	DNs	1.31	3.0T	T2*WI	Ferucarbotran	1.4 mL, ≥ 60 kg	25	8
Yoon et al[16]	2009	South Korea	28	51	32	WD-HCC	1.79				0.9 mL, < 60 kg	13	19
Yoo et al[8]	2009	South Korea	108	56	124	HCCs	3.00	3.0T	T2*WI	Ferucarbotran	1.4 mL, ≥ 60 kg	16	108
Yoo et al[8]	2009	South Korea	108	56	28	DNs					0.9 mL, < 60 kg	25	3
Okada et al[23]	2010	Japan	36	69	22	WD-HCC	1.40	1.5T	T2*WI	Ferucarbotran	0.45 mg Fe/kg	15	7
					15	MDPD-HCC	2.40					0	15
					4	DNs	1.60					4	0
Chou et al[25]	2011	Taiwan	12	56	11	HCC	2.30	1.5T	T2*WI	Ferucarbotran	1.4 mL, > 50 kg	3	8
Chou et al[25]	2011	Taiwan	12	56	6	Benign	1.60					6	0

DN: Nodular dysplasia; FNH: Focal nodular hyperplasia; HCC: Hepatocellular carcinoma; hyper: Hyperintensity; iso-/hypo: Isointensity/hypointensity; MD: Moderately-differentiated, NC: Not clear; PD: Poorly-differentiated; WD: Well-differentiated; MRI: Magnetic resonance imaging.